Clinical Trial Update: Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody [Phase 2]

View source ↗

Summary

A Phase 2 trial of NI-0801, an anti-CXCL10 monoclonal antibody, for primary biliary cholangitis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• NI-0801

Snippet

Sponsor: Light Chain Bioscience - Novimmune SA | Conditions: Primary Biliary Cirrhosis | Phase 2 | Status: TERMINATED